| langue originale | Anglais |
|---|---|
| Pages (de - à) | 1701-1703 |
| Nombre de pages | 3 |
| journal | Journal of Thoracic Oncology |
| Volume | 14 |
| Numéro de publication | 10 |
| Les DOIs |
|
| état | Publié - 1 oct. 2019 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Journal of Thoracic Oncology, Vol 14, Numéro 10, 01.10.2019, p. 1701-1703.
Résultats de recherche: Contribution à un journal › !!Comment/debate
TY - JOUR
T1 - Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?
AU - Remon, Jordi
AU - Hendriks, Lizza
AU - Aspeslagh, Sandrine
AU - Besse, Benjamin
N1 - Funding Information: Disclosures: Dr. Remon has received personal fees from OSE Immunotherapeutics; and has received other support from MSD, Boehringer, Pfizer , OSE Immunotherapeutics, Bristol-Myers Squibb , AstraZeneca , and Roche . Dr. Aspeslagh has received speaker fees from Roche, Amgen, AstraZeneca, Merck, Novartis, and Bristol-Myers Squibb. Dr. Besse reports grants from Abbvie, grants from Amgen, grants from AstraZeneca, grants from Biogen, grants from Blueprint Medicines, grants from BMS, grants from Celgène, grants from Eli-Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck KGaA, grants from MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, outside the submitted work. The remaining author declares no conflict of interest. Funding Information: Disclosures: Dr. Remon has received personal fees from OSE Immunotherapeutics; and has received other support from MSD, Boehringer, Pfizer, OSE Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche. Dr. Aspeslagh has received speaker fees from Roche, Amgen, AstraZeneca, Merck, Novartis, and Bristol-Myers Squibb. Dr. Besse reports grants from Abbvie, grants from Amgen, grants from AstraZeneca, grants from Biogen, grants from Blueprint Medicines, grants from BMS, grants from Celgène, grants from Eli-Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck KGaA, grants from MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, outside the submitted work. The remaining author declares no conflict of interest.
PY - 2019/10/1
Y1 - 2019/10/1
UR - http://www.scopus.com/inward/record.url?scp=85070499281&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2019.07.004
DO - 10.1016/j.jtho.2019.07.004
M3 - Comment/debate
C2 - 31420287
AN - SCOPUS:85070499281
SN - 1556-0864
VL - 14
SP - 1701
EP - 1703
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -